“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
ORGANIZATION
TRIPS Waiver Discussions Threaten Global Health Security: JPMA, IFPMA
Key international and regional biopharmaceutical associations issued a joint statement on June 10, rapping the move to waive intellectual property protections for COVID-19 vaccines, a topic up for discussion at an upcoming World Trade Organization (WTO) ministerial conference. The so-called…
To read the full story
Related Article
ORGANIZATION
- Japan Citizen’s Group Objects Pfizer’s Partnership with Tokyo Govt
February 1, 2023
- PhRMA Poised to Issue 2024 Reform Proposal in Next Few Months: New Japan Chief
January 25, 2023
- Kenporen Director Calls on Pharma Industry, MHLW to Share More Data toward FY2024 Reform
January 20, 2023
- JPMA Now Finalizing Policy Proposal 2023, Due Out “before Cherry Blossoms”
January 20, 2023
- Japan Pharma Lobbies Look Set to Shift to Okada/Ueno Leadership towards FY2024 Reform
January 17, 2023
Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…